Compare US Global Jets ETF (JETS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs ResMed Inc. — how do they compare? US Global Jets ETF trades at $30.55, while ResMed Inc. trades at $194.03 (market cap $28.81B). The key difference: ResMed Inc. pays a 1.21% dividend while US Global Jets ETF pays none, and US Global Jets ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| JETS | RMD | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $33.34 | $293.73 |
52-Week Low | $23.12 | $182.82 |
Market Cap | — | $28.81B |
Enterprise Value | — | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS trades at $30.58, up 0.39% with a mixed technical outlook showing bullish overall signals but bearish moving averages. The ETF faces headwinds from rising fuel costs, with U.S. airlines spending $6.66 billion on jet fuel in May 2026 (U.S. Transportation Department, 2026-07-07), though lower oil prices recently provided some relief. Recent news highlights volatility from Middle East conflicts and competitive pressure from defense-focused ETFs.
Outlook remains cautious due to cyclical exposure and fuel cost sensitivity. Investment opportunity hinges on sustained oil price declines, but risks include geopolitical tensions and airline profit pressures. Analyst sentiment is neutral with a Hold rating, emphasizing the ETF's concentration in industrials and high volatility.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
